What is the medical insurance reimbursement policy for adagrasib?

Adagrasib is an anticancer drug that targets KRAS G12C mutations and is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations. Since KRAS mutations have long been regarded as "undruggable" targets, the advent of adagrasib is considered an important breakthrough in the field of precision tumor treatment. However, the drug has not yet received official marketing approval in mainland China, and therefore has not yet been included in the national medical insurance catalog. Patients cannot obtain cost reductions through domestic medical insurance reimbursement.

Since it has not yet been launched in China, adagrasib is currently purchased mainly through overseas channels. The original drug is produced by Mirati Therapeutics in the United States. The price in the U.S. market is very high. Each box may cost up to hundreds of thousands of yuan, which is a heavy financial burden for ordinary patients. In addition, the drug has limited medical insurance coverage in the international market, and most countries still regard it as an innovative drug that needs to be purchased at out-of-pocket expense or is only available in clinical trials or special use programs.

In order to cope with the high drug prices, some patients choose to use generic versions imported from foreign channels, especially those produced by Lao pharmaceutical factories. The price of Laos's generic version of adagrasibu is relatively affordable, with each box costing about more than 3,000 yuan. Its active ingredients and dosage form are basically the same as the original drug, and it has high bioequivalence. It has become an important choice for many patients with high financial pressure. Although the price of generic drugs is lower, patients should still make sure to purchase through formal channels when choosing to avoid buying fake drugs or inferior products.

Generally speaking, since adagrasib has not yet been marketed in my country and has not entered the medical insurance system, patients can only choose to purchase the drug at their own expense and bear higher costs. In the future, if the drug is approved in China and included in the medical insurance catalog, it will greatly reduce the financial pressure on patients and improve drug accessibility. It is currently recommended that patients with KRAS G12C mutations can weigh the choice of original drugs or generic drugs under the guidance of doctors, combined with their own condition and economic conditions, and pay close attention to their domestic launch and medical insurance trends.

References：https://www.krazati.com/